BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bataille R, Jourdan M, Zhang XG, Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest. 1989;84:2008-2011. [PMID: 2592570 DOI: 10.1172/jci114392] [Cited by in Crossref: 345] [Cited by in F6Publishing: 52] [Article Influence: 11.1] [Reference Citation Analysis]
Number Citing Articles
1 Ikeguchi M, Hatada T, Yamamoto M, Miyake T, Matsunaga T, Fukumoto Y, Yamada Y, Fukuda K, Saito H, Tatebe S. Serum interleukin-6 and -10 levels in patients with gastric cancer. Gastric Cancer. 2009;12:95-100. [PMID: 19562463 DOI: 10.1007/s10120-009-0509-8] [Cited by in Crossref: 73] [Cited by in F6Publishing: 73] [Article Influence: 6.1] [Reference Citation Analysis]
2 Soresi M, Giannitrapani L, D'Antona F, Florena AM, La Spada E, Terranova A, Cervello M, D'Alessandro N, Montalto G. Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol. 2006;12:2563-2568. [PMID: 16688802 DOI: 10.3748/wjg.v12.i16] [Reference Citation Analysis]
3 Mahtouk K, Moreaux J, Hose D, Rème T, Meissner T, Jourdan M, Rossi JF, Pals ST, Goldschmidt H, Klein B. Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays. BMC Cancer. 2010;10:198. [PMID: 20465808 DOI: 10.1186/1471-2407-10-198] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
4 Avet-Loiseau H, Durie BG, Cavo M, Attal M, Gutierrez N, Haessler J, Goldschmidt H, Hajek R, Lee JH, Sezer O, Barlogie B, Crowley J, Fonseca R, Testoni N, Ross F, Rajkumar SV, Sonneveld P, Lahuerta J, Moreau P, Morgan G; International Myeloma Working Group. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia 2013;27:711-7. [PMID: 23032723 DOI: 10.1038/leu.2012.282] [Cited by in Crossref: 134] [Cited by in F6Publishing: 114] [Article Influence: 14.9] [Reference Citation Analysis]
5 van Zaanen HC, Koopmans RP, Aarden LA, Rensink HJ, Stouthard JM, Warnaar SO, Lokhorst HM, van Oers MH. Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. J Clin Invest 1996;98:1441-8. [PMID: 8823310 DOI: 10.1172/JCI118932] [Cited by in Crossref: 43] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
6 Slørdahl TS, Abdollahi P, Vandsemb EN, Rampa C, Misund K, Baranowska KA, Westhrin M, Waage A, Rø TB, Børset M. The phosphatase of regenerating liver-3 (PRL-3) is important for IL-6-mediated survival of myeloma cells. Oncotarget 2016;7:27295-306. [PMID: 27036022 DOI: 10.18632/oncotarget.8422] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
7 Hinson RM, Williams JA, Shacter E. Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2. Proc Natl Acad Sci U S A 1996;93:4885-90. [PMID: 8643498 DOI: 10.1073/pnas.93.10.4885] [Cited by in Crossref: 210] [Cited by in F6Publishing: 183] [Article Influence: 8.4] [Reference Citation Analysis]
8 Zanelli M, Ricci S, Zizzo M, Sanguedolce F, De Giorgi F, Palicelli A, Martino G, Ascani S. Systemic Mastocytosis Associated with "Smoldering" Multiple Myeloma. Diagnostics (Basel) 2021;11:88. [PMID: 33430341 DOI: 10.3390/diagnostics11010088] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Ahn IE, Mailankody S, Korde N, Landgren O. Dilemmas in treating smoldering multiple myeloma. J Clin Oncol 2015;33:115-23. [PMID: 25422486 DOI: 10.1200/JCO.2014.56.4351] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
10 Yen CH, Hsiao HH. NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma. Int J Mol Sci 2018;19:E3503. [PMID: 30405034 DOI: 10.3390/ijms19113503] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
11 Baran P, Hansen S, Waetzig GH, Akbarzadeh M, Lamertz L, Huber HJ, Ahmadian MR, Moll JM, Scheller J. The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling. J Biol Chem 2018;293:6762-75. [PMID: 29559558 DOI: 10.1074/jbc.RA117.001163] [Cited by in Crossref: 54] [Cited by in F6Publishing: 30] [Article Influence: 18.0] [Reference Citation Analysis]
12 Mughal TI, Girnius S, Rosen ST, Kumar S, Wiestner A, Abdel-Wahab O, Kiladjian JJ, Wilson WH, Van Etten RA. Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies. Leuk Lymphoma 2014;55:1968-79. [PMID: 24206094 DOI: 10.3109/10428194.2013.863307] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
13 Stone K, Woods E, Szmania SM, Stephens OW, Garg TK, Barlogie B, Shaughnessy JD Jr, Hall B, Reddy M, Hoering A, Hansen E, van Rhee F. Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levels. PLoS One 2013;8:e54610. [PMID: 23372742 DOI: 10.1371/journal.pone.0054610] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
14 Ohe Y, Podack ER, Olsen KJ, Miyahara Y, Miura K, Saito H, Koishihara Y, Ohsugi Y, Ohira T, Nishio K. Interleukin-6 cDNA transfected Lewis lung carcinoma cells show unaltered net tumour growth rate but cause weight loss and shortened survival in syngeneic mice. Br J Cancer 1993;67:939-44. [PMID: 8494727 DOI: 10.1038/bjc.1993.174] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 2.0] [Reference Citation Analysis]
15 Nair JR, Carlson LM, Koorella C, Rozanski CH, Byrne GE, Bergsagel PL, Shaughnessy JP Jr, Boise LH, Chanan-Khan A, Lee KP. CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment. J Immunol 2011;187:1243-53. [PMID: 21715687 DOI: 10.4049/jimmunol.1100016] [Cited by in Crossref: 65] [Cited by in F6Publishing: 50] [Article Influence: 6.5] [Reference Citation Analysis]
16 Burroughs Garcìa J, Eufemiese RA, Storti P, Sammarelli G, Craviotto L, Todaro G, Toscani D, Marchica V, Giuliani N. Role of 1q21 in Multiple Myeloma: From Pathogenesis to Possible Therapeutic Targets. Cells 2021;10:1360. [PMID: 34205916 DOI: 10.3390/cells10061360] [Reference Citation Analysis]
17 Fan JL, Zhang J, Dong LW, Fu WJ, Du J, Shi HG, Jiang H, Ye F, Xi H, Zhang CY, Hou J, Wang HY. URI regulates tumorigenicity and chemotherapeutic resistance of multiple myeloma by modulating IL-6 transcription. Cell Death Dis 2014;5:e1126. [PMID: 24625985 DOI: 10.1038/cddis.2014.93] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
18 Chen X, Wu Y, Jiang Y, Zhou Y, Wang Y, Yao Y, Yi C, Gou L, Yang J. Isoliquiritigenin inhibits the growth of multiple myeloma via blocking IL-6 signaling. J Mol Med (Berl) 2012;90:1311-9. [PMID: 22648519 DOI: 10.1007/s00109-012-0910-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
19 Nakano T, Chahinian AP, Shinjo M, Tonomura A, Miyake M, Togawa N, Ninomiya K, Higashino K. Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma. Br J Cancer 1998;77:907-12. [PMID: 9528833 DOI: 10.1038/bjc.1998.150] [Cited by in Crossref: 79] [Cited by in F6Publishing: 66] [Article Influence: 3.4] [Reference Citation Analysis]
20 Goto H, Shimazaki C, Tatsumi T, Yamagata N, Hirata T, Ashihara E, Oku N, Inaba T, Fujita N, Koishihara Y. Mouse anti-human interleukin-6 receptor monoclonal antibody inhibits proliferation of fresh human myeloma cells in vitro. Jpn J Cancer Res 1994;85:958-65. [PMID: 7961126 DOI: 10.1111/j.1349-7006.1994.tb02975.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
21 Greco C, Ameglio F, Alvino F, Mosiello A, Cianciulli AM, Venturo I, Del Monte G, Giampaolo M, Tong AW, Gandolfo GM. Phenotypic and genotypic alterations characterize patients bearing plasma cell dyscrasias with a high M-component. Cell Prolif 1999;32:231-8. [PMID: 10614712 DOI: 10.1046/j.1365-2184.1999.3240231.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
22 Korde N, Maric I. Myelomagenesis: capturing early microenvironment changes. Semin Hematol 2011;48:13-21. [PMID: 21232654 DOI: 10.1053/j.seminhematol.2010.11.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
23 Barut B, Chauhan D, Uchiyama H, Anderson KC. Interleukin-6 functions as an intracellular growth factor in hairy cell leukemia in vitro. J Clin Invest 1993;92:2346-52. [PMID: 8227350 DOI: 10.1172/JCI116839] [Cited by in Crossref: 27] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
24 Lin C, Shen H, Zhou S, Liu M, Xu A, Huang S, Shen C, Zhou F. Assessment of infection in newly diagnosed multiple myeloma patients: risk factors and main characteristics. BMC Infect Dis 2020;20:699. [PMID: 32972385 DOI: 10.1186/s12879-020-05412-w] [Reference Citation Analysis]
25 De Benedetti F, Massa M, Pignatti P, Albani S, Novick D, Martini A. Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest 1994;93:2114-9. [PMID: 8182142 DOI: 10.1172/JCI117206] [Cited by in Crossref: 171] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
26 Rajski M, Vogel B, Baty F, Rochlitz C, Buess M. Global gene expression analysis of the interaction between cancer cells and osteoblasts to predict bone metastasis in breast cancer. PLoS One 2012;7:e29743. [PMID: 22235336 DOI: 10.1371/journal.pone.0029743] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
27 Merico F, Bergui L, Gregoretti MG, Ghia P, Aimo G, Lindley IJ, Caligaris-Cappio F. Cytokines involved in the progression of multiple myeloma. Clin Exp Immunol 1993;92:27-31. [PMID: 8467562 DOI: 10.1111/j.1365-2249.1993.tb05943.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 2.2] [Reference Citation Analysis]
28 Yaccoby S, Pennisi A, Li X, Dillon SR, Zhan F, Barlogie B, Shaughnessy JD Jr. Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts. Leukemia 2008;22:406-13. [PMID: 18046446 DOI: 10.1038/sj.leu.2405048] [Cited by in Crossref: 65] [Cited by in F6Publishing: 55] [Article Influence: 4.6] [Reference Citation Analysis]
29 Li J, Favata M, Kelley JA, Caulder E, Thomas B, Wen X, Sparks RB, Arvanitis A, Rogers JD, Combs AP, Vaddi K, Solomon KA, Scherle PA, Newton R, Fridman JS. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support. Neoplasia 2010;12:28-38. [PMID: 20072651 DOI: 10.1593/neo.91192] [Cited by in Crossref: 57] [Cited by in F6Publishing: 47] [Article Influence: 5.2] [Reference Citation Analysis]
30 Papadopoulos NG, Georganas K, Skoutellas V, Konstantellos E, Lyritis GP. Correlation of interleukin-6 serum levels with bone density in postmenopausal women. Clin Rheumatol 1997;16:162-5. [PMID: 9093798 DOI: 10.1007/BF02247845] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
31 Dechow T, Steidle S, Götze KS, Rudelius M, Behnke K, Pechloff K, Kratzat S, Bullinger L, Fend F, Soberon V, Mitova N, Li Z, Thaler M, Bauer J, Pietschmann E, Albers C, Grundler R, Schmidt-Supprian M, Ruland J, Peschel C, Duyster J, Rose-John S, Bassermann F, Keller U. GP130 activation induces myeloma and collaborates with MYC. J Clin Invest 2014;124:5263-74. [PMID: 25384216 DOI: 10.1172/JCI69094] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
32 Barton BE. IL-6-like cytokines and cancer cachexia: consequences of chronic inflammation. Immunol Res. 2001;23:41-58. [PMID: 11417859 DOI: 10.1385/ir:23:1:41] [Cited by in Crossref: 67] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
33 Jurczyszyn A, Czepiel J, Biesiada G, Gdula-Argasińska J, Cibor D, Owczarek D, Perucki W, Skotnicki AB. HGF, sIL-6R and TGF-β1 Play a Significant Role in the Progression of Multiple Myeloma. J Cancer 2014;5:518-24. [PMID: 24963356 DOI: 10.7150/jca.9266] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
34 Teoh PJ, Chung TH, Chng PYZ, Toh SHM, Chng WJ. IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplification. Haematologica 2020;105:1391-404. [PMID: 31413087 DOI: 10.3324/haematol.2019.221176] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
35 Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol 2020;16:335-45. [PMID: 32327746 DOI: 10.1038/s41584-020-0419-z] [Cited by in Crossref: 97] [Cited by in F6Publishing: 68] [Article Influence: 97.0] [Reference Citation Analysis]
36 Isoda A, Matsumoto M, Nakahashi H, Mawatari M, Manaka A, Sawamura M. Reduced risk of bacterial infection in multiple myeloma patients with VAD regimen without intermittent high-dose dexamethasone. Int J Hematol 2011;93:59-65. [PMID: 21161620 DOI: 10.1007/s12185-010-0735-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
37 Soresi M, Giannitrapani L, D'Antona F, Florena AM, La Spada E, Terranova A, Cervello M, D'Alessandro N, Montalto G. Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol 2006;12:2563-8. [PMID: 16688802 DOI: 10.3748/wjg.v12.i16.2563] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 67] [Article Influence: 4.3] [Reference Citation Analysis]
38 Hilbert DM, Kopf M, Mock BA, Köhler G, Rudikoff S. Interleukin 6 is essential for in vivo development of B lineage neoplasms. J Exp Med 1995;182:243-8. [PMID: 7790819 DOI: 10.1084/jem.182.1.243] [Cited by in Crossref: 165] [Cited by in F6Publishing: 154] [Article Influence: 6.3] [Reference Citation Analysis]
39 Aschebrook-Kilfoy B, Zheng T, Foss F, Ma S, Han X, Lan Q, Holford T, Chen Y, Leaderer B, Rothman N, Zhang Y. Polymorphisms in immune function genes and non-Hodgkin lymphoma survival. J Cancer Surviv 2012;6:102-14. [PMID: 22113576 DOI: 10.1007/s11764-010-0164-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
40 Mondello P, Cuzzocrea S, Navarra M, Mian M. Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression. Oncotarget 2017;8:20394-409. [PMID: 28099912 DOI: 10.18632/oncotarget.14610] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
41 Chau GY, Wu CW, Lui WY, Chang TJ, Kao HL, Wu LH, King KL, Loong CC, Hsia CY, Chi CW. Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann Surg. 2000;231:552-558. [PMID: 10749617 DOI: 10.1097/00000658-200004000-00015] [Cited by in Crossref: 94] [Cited by in F6Publishing: 91] [Article Influence: 4.5] [Reference Citation Analysis]
42 Hassan SM, Khalaf MM, Sadek SA, Abo-Youssef AM. Protective effects of apigenin and myricetin against cisplatin-induced nephrotoxicity in mice. Pharm Biol 2017;55:766-74. [PMID: 28064632 DOI: 10.1080/13880209.2016.1275704] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 11.3] [Reference Citation Analysis]
43 Kang HS, Kim YH, Lee CS, Lee JJ, Choi I, Pyun KH. Anti-inflammatory effects of Stephania tetrandra S. Moore on interleukin-6 production and experimental inflammatory disease models. Mediators Inflamm 1996;5:280-91. [PMID: 18475741 DOI: 10.1155/S0962935196000415] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
44 Tucci M, Stucci S, Strippoli S, Dammacco F, Silvestris F. Dendritic cells and malignant plasma cells: an alliance in multiple myeloma tumor progression? Oncologist 2011;16:1040-8. [PMID: 21659611 DOI: 10.1634/theoncologist.2010-0327] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
45 Damas P, Ledoux D, Nys M, Vrindts Y, De Groote D, Franchimont P, Lamy M. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg. 1992;215:356-362. [PMID: 1558416 DOI: 10.1097/00000658-199204000-00009] [Cited by in Crossref: 533] [Cited by in F6Publishing: 481] [Article Influence: 18.4] [Reference Citation Analysis]
46 Birmann BM, Giovannucci E, Rosner B, Anderson KC, Colditz GA. Body mass index, physical activity, and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev 2007;16:1474-8. [PMID: 17627013 DOI: 10.1158/1055-9965.EPI-07-0143] [Cited by in Crossref: 56] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
47 Allegra A, Innao V, Allegra AG, Pugliese M, Di Salvo E, Ventura-Spagnolo E, Musolino C, Gangemi S. Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma. Int J Mol Sci 2019;20:E2822. [PMID: 31185596 DOI: 10.3390/ijms20112822] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
48 Zhang XG, Gu JJ, Lu ZY, Yasukawa K, Yancopoulos GD, Turner K, Shoyab M, Taga T, Kishimoto T, Bataille R. Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130. J Exp Med 1994;179:1337-42. [PMID: 8145045 DOI: 10.1084/jem.179.4.1337] [Cited by in Crossref: 175] [Cited by in F6Publishing: 152] [Article Influence: 6.5] [Reference Citation Analysis]
49 Schwabe M, Brini AT, Bosco MC, Rubboli F, Egawa M, Zhao J, Princler GL, Kung HF. Disruption by interferon-alpha of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor alpha- and beta-chains. J Clin Invest 1994;94:2317-25. [PMID: 7989587 DOI: 10.1172/JCI117596] [Cited by in Crossref: 42] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
50 Klein B, Tarte K, Jourdan M, Mathouk K, Moreaux J, Jourdan E, Legouffe E, De Vos J, Rossi JF. Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol 2003;78:106-13. [PMID: 12953803 DOI: 10.1007/BF02983377] [Cited by in Crossref: 148] [Cited by in F6Publishing: 67] [Article Influence: 8.2] [Reference Citation Analysis]
51 Pittari G, Vago L, Festuccia M, Bonini C, Mudawi D, Giaccone L, Bruno B. Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs. Front Immunol 2017;8:1444. [PMID: 29163516 DOI: 10.3389/fimmu.2017.01444] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 9.0] [Reference Citation Analysis]
52 Johnson PW, Selby PJ. The treatment of multiple myeloma--an important MRC trial. Br J Cancer 1994;70:781-5. [PMID: 7947081 DOI: 10.1038/bjc.1994.399] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]